An Evaluation of Acyclovir Prescribing Patterns in a Public Hospital in AlKharj

Nehad Ahmed1*, Abdulrahman Alharbi2, Ziyad S. Almalki1* and Mohammed Alhajri3

1Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharij, Saudi Arabia.
2Pharmacy Department, AlKharij Maternity and Children Hospital, Alkharij, Saudi Arabia.
3Department of Pharmacy, King Abdulaziz Medical City, Riyadh, Saudi Arabia.

Authors' contributions

This work was carried out in collaboration among all authors. Authors NA, AA and ZSA designed the study, performed the statistical analysis, wrote the protocol, wrote the first draft of the manuscript and managed the analyses of the study. Author MA managed the literature searches. All authors read and approved the final manuscript.

ABSTRACT

Aim: This study aimed to analyze acyclovir prescription patterns in a public hospital in AlKharij.
Methodology: Cross-sectional study, via hospital pharmacy services that included collecting data on acyclovir utilization from de-identified pharmacy records in maternity and children hospital in Alkharij from 1 Jan 2018 until 31 Aug 2020.
Results: A total of 1059 prescriptions contained acyclovir were dispensed between 1 Jan 2018 till 31 Aug 2020. In the present study, acyclovir was prescribed mainly as an intravenous (45.89%) or oral (34.09%) treatment. It is prescribed mainly as a vial (45.89%) followed by suspension (31.63%). Inpatient Ward prescribed 52.60% of the prescriptions and emergency department prescribed 25.87% of the prescriptions.
Conclusion: It can be concluded that acyclovir was prescribed commonly in the hospital and that its using should be monitored to ensure that it is prescribed and dispensed appropriately.

*Corresponding author: E-mail: n.ahmed@psau.edu.sa, z.almalki@psau.edu.sa
Keywords: Acyclovir; antimicrobial; antiviral; prescription patterns.

1. INTRODUCTION

Drug utilization was defined as the processes of prescribing, dispensing, and ingesting of drugs. Drug utilization studies are most interesting if focused on the most commonly used drugs [1]. Acyclovir is one of the most commonly used antiviral drugs for treating chickenpox-zoster and herpes simplex infections [2]. It is a synthetic acyclic purine nucleoside analog that is used for the treatment of initial episodes of herpes genitalis, suppression of remarkably frequent recurrences of herpes genitalis, and the acute treatment of varicella and herpes zoster [3]. Acyclovir is available in intravenous, oral, topical, or ophthalmic (not currently approved in the USA) treatments. Topical acyclovir is prepared as a 5% cream and ointment [4].

Several studies have shown that acyclovir was effective in treating many conditions. For example, a systematic review found that topical acyclovir was very effective in the treatment of acute herpes simplex virus epithelial keratitis [5]. According to the Herpetic Eye Disease Study, oral acyclovir was associated with a noteworthy reduction in the recurrence of keratitis during the study period [6]. Additionally, Mayer et al reported a decrease in recurrences of Herpes simplex virus following keratoplasty among patients with herpetic eye disease who received a longer course of therapy [7].

Rooij et al reported that during a 2-year follow-up period, oral acyclovir was associated with a reduction in herpetic eye disease recurrence in patients undergoing penetrating keratoplasty for herpes simplex virus [8]. Other systematic review showed the efficacy of three topical antivirals which are penciclovir, acyclovir and docosanol for the treatment of Herpes Simplex Labialis compared to placebo and stated that the three topical drugs are safe to use and have no serious adverse reactions [9].

But it should be used appropriately and only when needed because the inappropriate use of it increases the adverse effects, increases the resistance to the drug, and decrease its efficacy as shown in several studies [10-12]. Cunningham et al reported that the rate of resistance to acyclovir was less than 1% [10]. A second study conducted by Hlinomazová et al and reported that the prevalence of acyclovir resistance was 14 % among 212 patients with keratouveitis or keratitis who were treated systemically or locally [11]. Furthermore, a report in 1994 showed that using oral acyclovir as OTC for the treatment of genital herpes was rejected on the grounds due to the development of viral and accelerated microbial resistance that was caused by its overuse [12].

World Health Organization reported that drug utilization studies can contribute to national health policies that are designed to increase the availability of effective and safe medications and reported that drug utilization studies can support the concepts of therapeutic formularies and essential drugs [13]. This study aimed to analyze acyclovir prescription patterns in a public hospital in AlKharj, Saudi Arabia.

2. METHODOLOGY

A retrospective review of acyclovir drugs prescribed was conducted in maternity and children hospital in Alkhari from 1 Jan 2018 until 31 Aug 2020. The hospital is one of 17 maternity and children hospitals in Saudi Arabia and included 200 beds [14].

The study included the patients for whom acyclovir was prescribed by the attending or resident physician and dispensed by the pharmacy. A total of 1059 patients’ medical records were extracted during the period studies. The exclusion criteria included the patients who didn’t receive acyclovir or who received it before or after the study period.

The choice of the acyclovir regimen was at the discretion of the doctor in charge. Antivirals had been always given free of charge at the hospital’s pharmacy, where each prescription was computerized into a medical record, containing drugs and doses, dosage form (dose per pill and per day), amount of tablets delivered and date of dispensing. The descriptive data was extracted from de-identified pharmacy records and was represented as numbers and frequencies. All data were analyzed using the SPSS v13.0 software (SPSS Inc., Chicago, IL, USA).

3. RESULTS AND DISCUSSION

A total of 1059 prescriptions contained acyclovir were dispensed between 1 Jan 2018 till 31 Aug 2020. Sarnoff reported that acyclovir is given as
an intravenous, oral, topical, or ophthalmic treatment [4]. All of these treatments are approved in the USA except for ophthalmic treatment. Table 1 shows the type of acyclovir treatments that were prescribed during the study period.

### Table 1. Type of acyclovir treatments

| Type of treatment | Number N= | Percentage |
|-------------------|-----------|------------|
| Intravenous       | 486       | 45.89%     |
| Oral              | 361       | 34.09%     |
| Topical           | 184       | 17.37%     |
| Ophthalmic        | 28        | 2.64%      |
| Total             | 1059      | 100%       |

As shown in the results of the present study, acyclovir was prescribed mainly as an intravenous (45.89%) or oral (34.09%) treatment. It is prescribed mainly as a vial (45.89%) followed by suspension (31.63%). Table 2 shows the different dosage forms of acyclovir that were prescribed.

### Table 2. Dosage forms of acyclovir

| Dosage form of Acyclovir | Number N= | Percentage |
|--------------------------|-----------|------------|
| Suspension               | 335       | 31.63%     |
| Tablet                   | 26        | 2.46%      |
| Vial                     | 486       | 45.89%     |
| Ointment                 | 28        | 2.64%      |
| Cream                    | 184       | 17.37%     |
| Total                    | 1059      | 100%       |

Regarding the departments that prescribed acyclovir, Inpatient Ward prescribed 52.60% of the prescriptions and the emergency department prescribed 25.87% of the prescriptions as shown in Table 3.

### Table 3. Departments that prescribed acyclovir

| Department                  | Number N= | Percentage |
|-----------------------------|-----------|------------|
| Outpatient Department (OPD) | 68        | 6.42%      |
| Inpatient Ward (IPD)        | 557       | 52.60%     |
| Critical Care Unit (CCU)    | 160       | 15.11%     |
| Emergency Department (ER)   | 274       | 25.87%     |
| Total                       | 1059      | 100%       |

One of the most remarkable milestones in modern medical history has been the accomplishment of successful therapy for viral infections. This refers not only to the number of lives saved but also to the amount of research knowledge produced in connection with the day to day care of people with viral infections. Analyzes of patterns in antiviral prescribing medications are a valuable way to explore how medical procedure and research can improve the treatment of viral-infected patients on a continuous basis. Here, we showed that acyclovir was prescribed commonly. Similarly, previous studies showed a high percentage of acyclovir prescribing more than other antivirals. Forbes et al stated that 58.1% of the herpes zoster cases received an antiviral prescription. The most common prescribed antiviral was acyclovir (69.0%) [15]. In a study about patterns of use of acyclovir in a health maintenance organization population, Johnson et al stated that there were 6182 prescriptions for acyclovir during the study period of two years; about 47 percent of these prescriptions were oral acyclovir treatments [16].

Chaplin conducted a study about the current prescribing patterns for topical antiviral and antibacterial preparations in primary care in 2015 in England and reported that regarding the use of antivirals for skin infections, 98.64% of the prescriptions contained acyclovir and only 1.36% contained penciclovir [17]. He also reported that regarding the use of antivirals for eye infections, 40.62% of the prescriptions contained acyclovir and 59.38% contained ganciclovir [17].

FDA determines 2 warnings and precautions for Acyclovir. The first warning was for the topical use of recurrent HSV lesions on the external aspect of lips and the face. They said that Zovirax cream should not be applied on mucous membranes inside the mouth or nose or in the eye and the second warning was that there is a potential for irritation and contact sensitization [18].

Some limitations of our study should be acknowledged. First, associated factors not collected in the current, such as virus subtype, patients’ characteristics, prior treatment history, and clinician’s knowledge of emerging resistance, might have led to the patterns observed. Second, there has been no evaluation of combinations of different antivirals, helping to better explain the causes behind certain shifts in prescribing patterns.
4. CONCLUSION

The finding of this study suggests that acyclovir was prescribed commonly in the hospital and that most of the prescriptions were for systemic use as an intravenous or oral route. The use of it should be monitored because the unsuitable use increases adverse effects, increases drug interactions, increases the treatment cost, and decreases the efficacy of the drug.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT

As per university standard guideline, participant consent have been collected and preserved by the authors

ETHICAL APPROVAL

The study was approved by the central IRB Committee with an IRB log Number: 20-011E.

ACKNOWLEDGEMENT

This Publication was supported by the Deanship of Scientific Research at Prince Sattam bin Abdulaziz University.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Lunde PKM, Andrew M, Baksaa I. Drug Utilization-an instrument in drug research. In: Kewitz H, Roots I, Voight K, editors. In Epidemiological concepts in clinical pharmacology. Berlin: Springer-Verlag; 1987.
2. Bryan-Marrugo OL, Ramos-Jiménez J, Barrera-Saldaña H, Rojas-Martínez A, Vidaltamayo R, Rivas-Estilla AM. History and progress of antiviral drugs: from acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C. Med Univ. 2015; 17(68):165-174.
3. RxList. Zovirax (Acyclovir): Uses, Dosage, Side Effects, Interactions, Warning; 2020. Accessed 18 September 2020 Available:https://www.rxlist.com/zovirax-drug.htm#clinpharm>
4. Sarnoff DS. Treatment of recurrent herpes labialis. J Drugs Dermatol. 2014;13(9):1016-1018.
5. Guess S, Stone DU, Chodosh J. Evidence-based treatment of herpes simplex virus keratitis: A systematic review. Ocul Surf. 2007;5(3):240-250.
6. Anonymous. The Herpetic Eye Disease Study Group Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med. 1998;339(5):300-306.
7. Mayer K, Reinhard T, Reis A, Voiculescu A, Sundmacher R. Synergistic antitherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study. Graefes Arch Clin Exp Ophthalmol. 2003;241(12):1051-1054.
8. Van Rooij J, Rijneveld WJ, Remeijer L, Völker-Dieben HJ, Eggink CA, Geerards AJ et al. Effect of oral acyclovir after penetrating keratoplasty for herpetic keratitis: a placebo-controlled multicenter trial. Ophthalmology. 2003;110(10):1916-1919
9. Hammer KD, Dietz J, Lo TS, Johnson EM. A systematic review on the efficacy of topical acyclovir, penciclovir, and docosanol for the treatment of herpes simplex labialis. EMJ Dermatol. 2018;6(1):118-123.
10. Cunningham A, Griffiths P, Leone P, Mindel A, Patel R, Stanberry L et al. Current management and recommendations for access to antiviral therapy of herpes labialis. J Clin Virol. 2012;53(1):6–11.
11. Hlinomazová Z, Loukotová V, Horáčková M, Šerý O. The treatment of HSV1 ocular infections using quantitative real-time PCR results. Acta Ophthalmol. 2012;90(5):456–60.
12. The Kaiser Family Foundation. Puppem.com. Cost Containment
Strategies for Prescription Drugs: Assessing the Evidence in the Literature; 2020. Accessed 18 September 2020 Available: http://www.puprem.com/Documents/Cost-Containment-Strategies-for-prescription-Drugs-Assessing-The-Evidence-in-the-Literature-Report.pdf

13. World Health Organization. Regional Office for Europe & Dukes MNG. Drug utilization studies: Methods and uses. World Health Organization. Regional Office for Europe; 1993. Accessed 18 September 2020 Available: https://apps.who.int/iris/handle/10665/260517

14. Ministry of Health. MOH Publications - Media Report on the Eighth Anniversary of Pledge-Allegiance; 2020. Accessed 18 September 2020 Available: https://www.moh.gov.sa/en/Ministry/MediaCenter/Publications/Pages/Publications-2013-05-04-001.aspx>

15. Forbes HJ, Thomas SL, Smeeth L, Langan SM. Prescription of antiviral therapy after herpes zoster in general practice: who receives therapy?. Br J Gen Pract. 2012;62(605):e808–e814.

16. Johnson RE, Mullooly JP, Valanis BG, Andrews EB, Tilson HH. Acyclovir use and its surveillance in a general population. DICP. 1990;24(6):624-628.

17. Chaplin S. Topical antibacterial and antiviral agents: prescribing and resistance. Prescriber. 2016;27(7):29-36.

18. Food and Drug Administration. ZOVIRAX Cream; 2020. Accessed 18 September 2020 Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021478s007lbl.pdf

© 2020 Ahmed et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/61694